

**Investor Kit Third Quarter 2023** 

:. Cellebrite	FY 2020							FY 2021					FY 2022	FY 2023				
Cellebrite DI Ltd. Condensed and Consolid		Quarte	r Ended		Yr Ended		Quarte	r Ended		Yr Ended		Quarte	r Ended		Yr Ended		Quarter Ended	
(U.S. Dollars in thousands, except share and	31-Mar	30-Jun	30-Sep	31-Dec	31-Dec	31-Mar	30-Jun	30-Sep	31-Dec	31-Dec	31-Mar	30-Jun	30-Sep	31-Dec	31-Dec	31-Mar	30-Jun	30-Sep
Revenue:																		
Subscription services	\$ 22,597	\$ 24,405	\$ 25,841	\$ 27,771	\$ 100,614	\$ 28,974	\$ 29,870	\$ 30,046	\$ 31,999	\$ 120,889	\$ 36,361	\$ 36,446	\$ 39,385	\$ 43,698	\$ 155,890	\$ 47,367	\$ 50,512	\$ 54,150
Term-license	2,926	6,763	9,163	10,279	29,131	11,547	11,588	21,205	18,088	62,428	11,824	13,395	16,209	18,625	60,053	13,915	16,694	19,130
Total subscription	25,523	31,168	35,004	38,050	129,745	40,521	41,458	51,251	50,087	183,317	48,185	49,841	55,594	62,323	215,943	61,282	67,206	73,280
Other non-recurring*	7,960	10,506	11,838	11,832	42,136	7,743	10,382	6,657	9,387	34,169	5,972	4,200	7,407	3,666	21,245	2,918	1,972	4,185
Professional services	5,251	4,096	6,399	7,286	23,032	5,019	7,328	7,979	8,434	28,760	8,228	8,532	8,674	8,029	33,463	7,034	7,506	6,714
Total revenue	38,734	45,770	53,241	57,168	194,913	53,283	59,168	65,887	67,908	246,246	62,385	62,573	71,675	74,018	270,651	71,234	76,684	84,179
Cost of revenue:																		
Subscription services	2,195	2,268	2,278	2,054	8,795	2,482	2,192	2,650	2,045	9,369	3,768	4,576	5,082	3,681	17,107	4,492	4,946	4,602
Term-license	137	222	577	773	1,709	357	538	651	753	2,299	250	178	7	50	485	2	0	4
Other non-recurring*	2,423	2,117	1,930	2,900	9,370	1,060	1,816	2,282	4,659	9,817	2,207	3,256	4,108	3,381	12,952	2,981	2,926	3,515
Professional services	4,884	3,612	4,716	4,793	18,005	4,300	5,522	6,371	4,879	21,072	4,758	5,088	5,337	5,019	20,202	4,931	5,159	4,757
otal cost of revenue	9,639	8,219	9,501	10,520	37,879	8,199	10,068	11,954	12,336	42,557	10,983	13,098	14,534	12,131	50,746	12,406	13,031	12,878
Gross profit	29,095	37,551	43,740	46,648	157,034	45,084	49,100	53,933	55,572	203,689	51,402	49,475	57,141	61,887	219,905	58,828	63,653	71,301
perating expenses:																		
Research and development	13.005	13.702	12.899	14,771	54.377	14.893	15.388	16.427	18.833	65.541	19.576	19.675	21.635	19.734	80.620	21.131	21.053	20,451
Sales and marketing	15,336	13.044	15.162	17.763	61.305	16.518	18.509	20.123	21,239	76.389	23.259	24.892	25,567	23.669	97.387	27.601	26.745	26.873
General and administrative	7.252	9.140	6.696	8,357	31,445	9.286	6.982	20.475	11,194	47.937	10.513	10.507	11.024	8.810	40.854	9,960	11.232	10.498
Other	-	-	-	689	689	-	-	-	· -	-	· -	· -	-	· <u>-</u>	· -	· -	· -	-
otal operating expenses	35,593	35,886	34,757	41,580	147,816	40,697	40,879	57,025	51,266	189,867	53,348	55,074	58,226	52,213	218,861	58,692	59,030	57,822
perating (loss) income	[6,498]	1,665	8,983	5,068	9,218	4,387	8,221	[3,092]	4,306	13,822	[1,946]	[5,599]	(1,085)	9,674	1,044	136	4,623	13,479
inancial (expense) Income, net	142	1,015	417	605	2,179	366	496	17,812	49,809	68,483	56,400	38,466	25,422	[572]	119,716	[38,775]	[36,051]	[6,630]
ncome (loss) before taxes on income	(6,356)	2,680	9,400	5,673	11,397	4,753	8,717	14,720	54,115	82,305	54,454	32,867	24,337	9,102	120,760	[38,639]	(31,428)	6,849
ax (income) expense	901	717	1,279	2,719	5,616	1,163	921	6,581	2,244	10,909	[984]	(330)	[755]	2,024	[45]	1,966	920	349
Vet Income (loss)	\$ [7,257]	\$ 1,963	\$ 8,121	\$ 2,954	\$ 5,781	\$ 3,590	\$ 7,796	\$ 8,139	\$ 51,871	\$ 71,396	\$ 55,438	\$ 33,197	\$ 25,092	\$ 7,078	\$ 120,805	\$ (40,605)	\$ [32,348]	\$ 6,500
Diluted net earnings (loss) per share Pro-forma weighted average number of	\$ (0.09)	\$ (0.01)	\$ 0.03	\$ (0.01)	\$ (0.08)	\$ (0.001)	\$ 0.02	\$ 0.05	\$ 0.25	\$ 0.44	\$ 0.27	\$ 0.17	\$ 0.13	\$ 0.04	\$ 0.59	\$ [0.21]	\$ [0.17]	\$ 0.03
hares used to compute diluted net																		
arnings per share	128,486,397	123,337,827	157,968,025	123,773,763	123,696,624	130,077,090	125,404,745	163,348,212	199,082,479	161,538,579	196,142,739	192,133,157	193,188,295	192,786,615	195,393,558	198,184,236	199,704,722	204,394,330
ross margin	75.1%	82.0%	82.2%	81.6%	80.6%	84.6%	83.0%	81.9%	81.8%	82.7%	82.4%	79.1%	79.7%	83.6%	81.3%	82.6%	83.0%	84.7%
R&D % of total revenue	33.6%	29.9%	24.2%	25.8%	27.9%	28.0%	26.0%	24.9%	27.7%	26.6%	31.4%	31.4%	30.2%	26.7%	29.8%	29.7%	27.5%	24.3%
S&M % of total revenue	39.6%	28.5%	28.5%	31.1%	31.5%	31.0%	31.3%	30.5%	31.3%	31.0%	37.3%	39.8%	35.7%	32.0%	36.0%	38.7%	34.9%	31.9%
G&A % of total revenue	18.7%	20.0%	12.6%	14.6%	0.4%	17.4%	11.8%	31.1%	16.5%	19.5%	16.9%	16.8%	15.4%	11.9%	15.1%	14.0%	14.6%	12.5%
otal Operating Expenses % of total revenues	91.9%	78.4%	65.3%	71.5%	75.8%	76.4%	69.1%	86.5%	75.5%	77.1%	85.5%	88.0%	81.2%	70.5%	80.9%	82.4%	77.0%	68.7%
perating margin	-16.8%	3.6%	16.9%	10.1%	4.7%	8.2%	13.9%	-4.7%	6.3%	5.6%	-3.1%	-8.9%	-1.5%	13.1%	0.4%	0.2%	6.0%	16.0%
ax rate	-14.2%	26.8%	13.6%	47.9%	49.3%	24.5%	10.6%	44.7%	4.1%	13.3%	-2.3%	-1.0%	-3.1%	22.2%	0.0%	-5.1%	-2.9%	5.1%
Net margin	-18.7%	4.3%	15.3%	6.4%	3.0%	6.7%	13.2%	12.4%	76.4%	29.0%	88.9%	53.1%	35.0%	9.6%	44.6%	-57.0%	-42.2%	7.7%

<sup>\*</sup>Other non-recurring revenue is composed of hardware sales, usage fees and perpetual licenses, and was previously referred to "Perpetual license and other," Changing the name for this type of revenue.

rite
l

•· Cellebrite			FY 2020					FY 2021					FY 2022		FY 2023			
Cellebrite DI Ltd. Condensed and Consolid		Quarte	r Ended		Yr Ended		Quarte	r Ended		Yr Ended		Quarte	r Ended		Yr Ended		Quarter Ended	
(U.S. Dollars in thousands, except share and	31-Mar	30-Jun	30-Sep	31-Dec	31-Dec	31-Mar	30-Jun	30-Sep	31-Dec	31-Dec	31-Mar	30-Jun	30-Sep	31-Dec	31-Dec	31-Mar	30-Jun	30-Sep
-																		
Revenue:																		
Subscription services	\$ 22,597	\$ 24,405	\$ 25,841	\$ 27,771	\$ 100,614	\$ 28,974	\$ 29,870	\$ 30,046	\$ 31,999	\$ 120,889	\$ 36,361	\$ 36,446	\$ 39,385	\$ 43,698	\$ 155,890	\$ 47,367	\$ 50,512	\$ 54,150
Term-license	2,926	6,763	9,163	10,279	29,131	11,547	11,588	21,205	18,088	62,428	11,824	13,395	16,209	18,625	60,053	13,915	16,694	19,130
Total subscription	25,523	31,168	35,004	38,050	129,745	40,521	41,458	51,251	50,087	183,317	48,185	49,841	55,594	62,323	215,943	61,282	67,206	73,280
Other non-recurring*	7,960	10,506	11,838	11,832	42,136	7,743	10,382	6,657	9,387	34,169	5,972	4,200	7,407	3,666	21,245	2,918	1,972	4,185
Professional services	5,251	4,096	6,399	7,286	23,032	5,019	7,328	7,979	8,434	28,760	8,228	8,532	8,674	8,029	33,463	7,034	7,506	6,714
Fotal revenue	38,734	45,770	53,241	57,168	194,913	53,283	59,168	65,887	67,908	246,246	62,385	62,573	71,675	74,018	270,651	71,234	76,684	84,179
Cost of revenue:																		
Subscription services	2.176	2.252	2.257	2.031	8,716	2,460	2,170	2,610	2,130	9,370	3,768	4,576	5.082	3,681	17,107	4,492	4,946	4,602
Term-license	137	222	577	773	1.709	357	538	651	754	2.300	252	178	7	50	487	2	-	4,002
Other non-recurring*	2.423	2.117	1.930	2.900	9.370	1.060	1.816	2.282	4.655	9.813	2.189	3.236	4.084	3.356	12.865	2.954	2.893	3.485
Professional services	4.861	3.541	4.658	4.722	17.781	4.244	5.473	6.252	4,726	20.695	4 528	4.769	5.007	4 699	19,003	4,559	4.764	4,340
Total cost of revenue	9.597	8.131	9,422	10.426	37.576	8.121	9,997	11.795	12.265	42.178	10.737	12.759	14.180	11.786	49.462	12.007	12,603	12.431
- Install Cost of Teveride	7,377	0,131	7,422	10,420	37,370	0,121		11,773	12,203	42,176	10,737	12,737	14,180	11,700	47,462	12,007	12,003	12,431
Gross profit	29,137	37,639	43,819	46,742	157,337	45,162	49,171	54,092	55,643	204,068	51,648	49,814	57,495	62,232	221,189	59,227	64,081	71,748
Operating expenses:																		
Research and development	12,366	12,355	11,863	13,745	50,329	13,727	14,125	14,912	17,376	60,140	17,777	18,154	19,964	18,174	74,069	19,698	19,204	19,203
Sales and marketing	14,320	12,848	13,664	16,829	57,661	15,257	17,206	18,286	21,654	72,403	21,890	23,234	24,106	22,122	91,352	25,368	25,249	24,470
General and administrative	5,332	5,155	5,707	6,625	22,819	5,983	6,385	7,426	8,862	28,656	9,347	9,362	10,013	7,508	36,230	8,508	10,233	8,823
otal operating expenses	32,018	30,358	31,234	37,199	130,809	34,967	37,716	40,624	47,892	161,199	49,014	50,750	54,083	47,804	201,651	53,574	54,686	52,496
Non-GAAP operating income (loss)	[2,881]	7,281	12,585	9,543	26,528	10,195	11,455	13,468	7,751	42,869	2,634	[936]	3,412	14,428	19,538	5,653	9,395	19,252
Financial Income, net	142	1,015	417	605	2,179	366	496	17,812	49,809	68,483	56,400	38,466	25,422	[572]	119,716	[38,775]	[36,051]	[6,630
Income (loss) before taxes on income	[2,739]	8,296	13,002	10,148	28,707	10,561	11,950	31,280	57,560	111,352	59,034	37,530	28,834	13,856	139,254	[33,122]	[26,656]	12,622
ax (income) expense	901	717	1,279	2,719	5,616	1,163	921	6,581	2,244	10,909	[984]	(330)	(755)	2,024	[45]	1,966	920	349
Income tax adjustment	[78]	[417]	[207]	[441]	[1,142]	(804)	(154)	(1,210)	498	(1,670)	[425]	506	(981)	516	(384)	1,194	131	(440
One time tax (income) expense	-	-	-	-	-	-	-	7,067	-	7,067	(1,825)	-	[543]	-	(2,368)	-	-	-
inance (income) expense	-	-	-	-	-	-	-	[17,252]	(50,621)	(67,873)	[56,348]	(38,391)	[25,091]	2,967	(116,863)	40,793	38,160	9,480
Non-GAAP net income (loss)	\$ (3,718)	\$ 7,162	\$ 11,516	\$ 6,988	\$ 21,949	\$ 8,594	\$ 10,876	\$ 13,304	\$ 5,193	\$ 37,966	\$ 1,420	\$ (25)	\$ 2,974	\$ 15,315	\$ 19,684	\$ 6,899	\$ 10,715	\$ 21,313
Diluted net earnings (loss) per share	\$ (0.03)	\$ 0.06	\$ 0.07	\$ 0.06	\$ 0.18	\$ 0.07	\$ 0.09	\$ 0.08	\$ 0.03	\$ 0.24	\$ 0.01	\$ (0.00)	\$ 0.01	\$ 0.08	\$ 0.10	\$ 0.03	\$ 0.05	\$ 0.09
Pro-forma weighted average number of																		
shares used to compute diluted net																		
earnings per share	128,486,397	123,337,827	157,968,025	123,773,763	123,696,624	130,077,090	125,404,745	163,348,212	199,082,479	161,538,579	196,142,739	192,133,157	193,188,295	192,786,615	195,393,558	198,184,236	199,704,722	204,394,330
Gross margin	75.2%	82.2%	82.3%	81.8%	80.7%	84.8%	83.1%	82.1%	81.9%	82.9%	82.8%	79.6%	80.2%	84.1%	81.7%	83.1%	83.6%	85.2%
R&D % of total revenue	31.9%	27.0%	22.3%	24.0%	25.8%	25.8%	23.9%	22.6%	25.6%	24.4%	28.5%	29.0%	27.9%	24.6%	27.4%	27.7%	25.0%	22.8%
S&M % of total revenue	37.0%	28.1%	25.7%	29.4%	29.6%	28.6%	29.1%	27.8%	31.9%	29.4%	35.1%	37.1%	33.6%	29.9%	33.8%	35.6%	32.9%	29.1%
G&A % of total revenue	13.8%	11.3%	10.7%	11.6%	11.7%	11.2%	10.8%	11.3%	13.1%	11.6%	15.0%	15.0%	14.0%	10.1%	13.4%	11.9%	13.3%	10.5%
Fotal Operating Expenses % of total revenues	82.7%	66.3%	58.7%	65.1%	67.1%	65.6%	63.7%	61.7%	70.5%	65.5%	78.6%	81.1%	75.5%	64.6%	74.5%	75.2%	71.3%	62.4%
perating margin	-7.4%	15.9%	23.6%	16.7%	13.6%	19.1%	19.4%	20.4%	11.4%	17.4%	4.2%	-1.5%	4.8%	19.5%	7.2%	7.9%	12.3%	22.9%
ax rate	-35.7%	13.7%	11.4%	31.1%	23.5%	18.6%	9.0%	47.5%	3.0%	17.6%	-4.0%	-2.2%	-1.1%	10.9%	-1.5%	-2.3%	-3.0%	6.3%
Net margin	-9.6%	15.6%	21.6%	12.2%	11.3%	16.1%	18.4%	20.2%	7.6%	15.4%	2.3%	0.0%	4.1%	20.7%	7.3%	9.7%	14.0%	25.3%

\*Other non-recurring revenue is composed of hardware sales, usage fees and perpetual licenses, and was previously referred to "Perpetual license and other." Changing the name for this type of revenue reflects that perpetual license revenue has declined to relatively insignificant levels with hardware sales now representing the majority of this type of revenue.

Cellebrite		FY	2020			FY	2021			FY	2022				FY 20	23	
Cellebrite DI Ltd. Condensed and Consolidated - Balance Sheets		Quarter Ende	Н	Yr Ended		Quarter Ende	1	Yr Ended	l	Quarter Ende	1	Yr Ended	Quarter Ended				
[U.S. Dollars in thousands]	31-Mar	30-Jun	30-Sep	31-Dec	31-Mar	30-Jun	30-Sep	31-Dec	31-Mar	30-Jun	30-Sep	31-Dec	3	1-Mar	30-J		30-Sep
ASSETS																	
Current Assets																	
Cash and cash equivalents	\$ 66,265	\$ 41,251	\$ 113,020	\$ 128,709	\$ 134,838	\$ 166,286	\$ 109,886	\$ 145,973	\$ 125,719	\$ 91,685	\$ 84,566	\$ 87,645	\$	98,972		10,502	\$ 137,066
Marketable securities Restricted cash	5.129	5.141	- 5,138	5,137	5.127	5.107	-	-	22,735	32,435	43,409 -	44,643 -		48,938		57,605	46,315 -
Short-term deposits	101,709	147,862	91,875	108,928	101,421	79,848	61,801	35,592	17,473	18,394	18,561	51,335		54,740		69,151	80,359
Trade receivables	41,875	41,276	59,807	66,324	59,585	52,283	76,215	67,505	60,297	66,746	88,581	78,761		69,594		61,194	69,559
Prepaid expenses and other current assets	7,257	6,804	7,298	7,439	7,370	9,919	14,055	12,818	11,596	11,665	13,019	17,085		20,259		22,185	24,476
Contract acquisition costs	2,168	2,382	2,629	2,979	3,122	3,761	4,563	4,813	4,456	4,601	5,018	6,286		6,377		5,946	5,325
Inventories	4,452 228.855	5,021	4,624 284,391	4,754 324,270	4,865 316,328	4,857 322,061	4,808	6,511 273,212	7,858 250.134	8,116	9,350	10,176 295,931		11,405 310.285		10,822 37,405	11,210 374,310
Total current assets	228,855	249,/3/	284,391	324,270	316,328	322,061	2/1,328	2/3,212	250,134	233,642	262,504	295,931		310,285		37,405	3/4,310
Non-current assets																	
Other non-current assets Marketable securities	345	237	204	565	2,314	4,872	179	1,958	1,990 6,475	1,826 22,831	1,825 21,266	1,731 22,125		2,657 18,521		2,792 7,297	7,572 19,494
Deferred tax assets	4.213	3,797	3,419	7.372	8,265	8,114	9,475	9.800	10,881	12.038	12.628	12,123		11,894		11,997	9,601
Property and equipment, net	15,975	16,668	16,599	16,106	16,285	16,608	16,392	16,756	17,752	17,775	17,634	17,259		16,725		15,810	15,274
Intangible assets, net	7,771	7,385	6,998	6,611	6,225	8,788	8,312	11,228	10,564	9,901	9,808	11,254		10,458		9,618	11,155
Operating lease right-of-use assets, net	-	-	-	-	-	-	-	-	-	-	-	15,653		15,320		14,145	12,707
Goodwill	9,463	9,463	9,463	9,463	9,463	9,463	9,463	26,829	26,829	26,829	26,829	26,829		26,829		26,829	26,829
Total non-current assets	37,767	37,550	36,683	40,117	42,552	47,845	43,821	66,571	74,491	91,200	89,990	107,362		102,404		38,488	102,632
<u>Total Assets</u>	\$ 266,622	\$ 287,287	\$ 321,074	\$ 364,387	\$ 358,880	\$ 369,906	\$ 315,149	\$ 339,783	\$ 324,625	\$ 324,842	\$ 352,494	\$ 403,293	\$	412,689	\$ 43	25,893	\$ 476,942
Liabilities, redeemable convertible preferred shares and shareholde	rs' equity (defici	ency)															
Current Liabilities																	
Trade payables	\$ 5,554	\$ 3,910	\$ 2,985	\$ 4,727	\$ 4,525	\$ 4,419	\$ 5,756	\$ 9,546	\$ 9,288	\$ 3,775	\$ 4,716	\$ 4,612	\$	4,918	\$	4,991	\$ 7,985
Other accounts payable and accrued expenses	23,884	29,148	36,137	49,112	39,431	44,448	51,732	54,044	43,483	47,453	49,424	45,453		37,198		35,618	43,494
Deferred revenues	68,960	77,190	90,860	105,543	103,950	102,327	115,017	122,983	117,785	121,645	135,642	152,709		157,903	1	58,942	170,659
Operating lease liabilities Total current liabilities	98,398	110,248	129,982	159,382	147,906	151,194	172,505	186,573	170,556	172,873	189,782	5,003 <b>207,777</b>		4,723 204,742		4,955 04,506	4,700 226,838
rotat current dabitates	70,070	110,240	127,702	107,002	147,700	101,174	172,000	100,070	170,000	172,070	107,702	207,777		204,742		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	220,000
Long-term Liabilities	0.544	E 0/4	0/.550	4 555	/ 800	( 001	2.015	0.500	( 000	/ 500	( 000	E 00/		F 500		F 0 / F	F 000
Other long term liabilities Long-term deferred revenues	3,541 19,406	5,241 22,426	26,558 5,560	6,557 33,439	6,700 34,900	6,901 33,038	7,015 34,398	9,539 36,426	6,877 35,167	6,580 35,476	6,202 36,285	5,394 42,173		5,577 48,384		5,047 47,469	5,080 47,596
Restricted Sponsor Shares liability	17,400	22,420	3,300	33,437	34,700	33,030	55,893	44,712	31,206	22,600	16,151	17,532		28,574		37.625	40,272
Price Adjustment Shares liability	-	-	-	-	_	-	103,338	79,404	53,645	37,798	24,973	26,184		46,126		62,781	67,560
Derivative warrant liabilities	=		-	-	-	-	71,984	56,478	39,395	25,457	19,640	20,015		29,824		42,278	44,332
Operating lease liabilities									l			10,353		10,105		8,631	7,322
Total long-term liabilities	22,947	27,667	32,118	39,996	41,600	39,939	272,628	226,559	166,290	127,911	103,251	121,651		168,590	2	03,831	212,162
Total Liabilities	\$ 121,345	\$ 137,915	\$ 162,100	\$ 199,378	\$ 189,506	\$ 191,133	\$ 445,133	\$ 413,132	\$ 336,846	\$ 300,784	\$ 293,033	\$ 329,428	\$	373,332	\$ 41	08,337	\$ 439,000
Redeemable convertible preferred shares	101,205	101,205	101,205	101,205	101,205	101,205	-	-	-	=	-	-					-
Shareholders' equity (deficiency)																	
Share capital	* -	* -	* _	* -	* -	* -	* -	* -	* -	* _	* -	* -		* _		* -	* -
Additional paid-in capital	27,285	29,369	31,194	34,226	35,925	37,815	[156,339]	(153,072)	(146,587)	[141,921]	(131,845)	(125,624)		[119,061]	(1	08,166)	[95,155]
Treasury stock, NIS 0.00001 par value; 41,776 ordinary shares		(85)	(85)	(85)	(85)	(85)	(85)	(85)	(85)	(85)	(85)	(85)		(85)		(85)	(85)
Accumulated other comprehensive income Retained earnings	1,482 15,305	1,617 17,266	1,273 25,387	1,321 28,342	397 31,932	110 39,728	(78) 26,518	1,372 78,436	575 133,876	(1,009) 167,073	(774) 192,165	331 199,243		(135) 158,638	1	(483) 26,290	392 132,790
Total shareholders' equity (deficiency)	44,072	48,167	57,769	63,804	68,169	77,568	[129,984]	[73,349]	[12,221]	24,058	59,461	73,865		39,357		17,556	37,942
													_				
Total liabilities, redeemable convertible preferred shares and share	holc \$ 266,622	\$ 287,287	\$ 321,074	\$ 364,387	\$ 358,880	\$ 369,906	\$ 315,149	\$ 339,783	\$ 324,625	\$ 324,842	\$ 352,494	\$ 403,293	\$	412,689	\$ 43	25,893	\$ 476,942

<sup>\*</sup> Less than US\$ 1.

<b>∵</b> Cellebrite		FY 2020						FY 2021					FY 2022			FY 2023			
Cellebrite DI Ltd. Condensed and Consolidated - Quarterly US GAAP Cash Flows	31-Mar		er Ended	21. D	Yr Ended	31-Mar		r Ended	01. D	Yr Ended	31-Mar		r Ended	01.0	Yr Ended			uarter Ended 30-Jun	20.5
(U.S. Dollars in thousands - unaudited)	31-Mar	30-Jun_	30-Sep	31-Dec	31-Dec	31-Mar_	30-Jun	30-Sep	31-Dec	31-Dec	31-Mar_	30-Jun_	30-Sep	31-Dec	31-Dec	31-	-Mar	30-Jun	30-Sep
Cash flows from operating activities:																			
Net income (loss)	\$ [7,257]	\$ 1,963	\$ 8,121	\$ 2,954	\$ 5,781	\$ 3,590	\$ 7,796	\$ 8,139	\$ 51,871	\$ 71,396	\$ 55,438	\$33,197	\$25,092	\$ 7,078	\$ 120,805	\$	[40,605]	\$ (32,348)	\$ 6,500
Adjustments to reconcile net income to net cash provided by (used in) operating activities:																			
Employees' stock option compensation and RSU's	1,822	2,084	1,825	1,540	7,271	1,699	1,703	1,417	1,661	6,480	2,858	3,605	3,458	3,787	13,708		4,457	4,600	4,881
Amortization of premium and discount and accrued interest on marketable securities	-	-	-	-			-	-	-		17	(55)	[109]	[225]	(372)		(171)	(290)	(337)
Depreciation and amortization	1,151	1,506	1,689	1,533	5,879	1,482	1,698	2,097	1,814	7,091	2,112	2,257	2,305	2,520 [318]	9,194		2,447	2,569	2,380
Interest income from short term deposits  Deferred income taxes	506	417	378	[4,119]	(2,818)	[342] [703]	(147) 134	[1.338]	269	(1.638)	(62) [924]	(137) (918)	[167] [489]	(61)	(684) (2,392)		(684) 560	(1,713) (98)	(1,845) 2.373
Revaluation of derivative warrants	200	417	3/0	[4,117]	[2,010]	[/03]	134	3,539	[15,506]	[11,967]	[17,083]	[13,938]	[5,817]	375	[36,463]		9,809	12,454	2,054
Remeasurement of Restricted Sponsor Shares liability	_	_	_	_	_	_	_	[6,454]	(11,181)	[17,635]	[13,506]	(8,606)	[6,449]	1.381	(27,180)		11,042	9,051	2,647
Remeasurement of Price Adjustment Shares liability	_	_	_	_	_	_	_	(14,337)	(23,934)	(38,271)	[25,759]	[15,847]	[12,825]	1,211	(53,220)		19,942	16,655	4,779
Other	_	_	_	689	689	_	_	-	-	-	-	-	-	-				-	-
(Increase) Decrease in trade receivables	3,466	659	[18,259]	(5,597)	(19,731)	6,237	7,472	(24,357)	8,690	(1,958)	7,015	(7,765)	[23,377]	11,242	(12,885)		9,627	8,490	(8,779)
Increase (Decrease) in deferred revenue	558	10,789	16,255	20,136	47,738	1,248	(3,940)	15,344	9,152	21,804	(5,916)	7,858	18,071	18,953	38,966		10,468	87	13,312
Decrease (Increase) in other non-current assets	[24]	12	33	314	335	[1,749]	(2,559)	4,693	[1,779]	[1,394]	(33)	166	-	94	227		[927]	(135)	[4,779]
(Increase) Decrease in prepaid expenses and other current assets	[626]	881	[401]	(193)	(339)	[2,009]	(3,149)	[5,687]	2,541	(8,304)	750	180	[2,191]	(4,431)	(5,692)		(3,637)	[1,987]	[1,412]
Changes in operating lease assets	-	-	-	-	-	-	-	-	-	-	-	-	-	4,667	4,667		1,367	1,333	1,438
Changes in operating lease liability	-	-	-	-	-	-	-	-	-	-	-	-	-	(5,955)	(5,955)		[1,562]	[1,400]	[1,564]
(Increase) deacrease in inventories	[429]	[567]	403	(100)	(693)	[138]	15	36	(1,711)	[1,798]	[1,347]	[274]	[1,247]	[812]	(3,680)		(1,225)	583	(396)
Increase (Decrease) in trade payables	[193]	(1,898)	(1,009)	1,667	[1,433]	[59]	[235]	1,494	2,955	4,155	[352]	(5,421)	1,197	[895]	(5,471)		264	117	2,989
Increase (Decrease) in other accounts payable and accrued expenses	(3,983)	6,924	6,852	12,656	22,449	(9,523)	4,953	7,249	2,428	5,107	[11,085]	1,922	2,370	(2,060)	(8,853)		[8,879]	(862)	4,904
(Decrease) increase in other long-term liabilities	(11)	22,780	749 16,636	32,114	1,382 66,510	143	13,942	[8,047]	2,522	2,984 36,052	[10,537]	[4,073]	[378]	35,743	[4,143] 20,577		183	16,576	29,178
Net cash (used in) provided by operating activities	[5,020]		16,636	32,114	66,510	[124]	13,942	[8,047]		36,052	[10,537]	[4,0/3]	[556]	35,743	20,577		12,4/6	16,576	29,178
Cash flows from investing activities:																			
Purchase of property and equipment	[1,998]	[1,629]	[1,162]	[1,392]	[6,181]	[1,308]	[1,546]	[1,479]	[778]	(5,111)	(2,305)	[1,571]	[1,630]	[1,391]	[6,897]		[1,064]	[825]	[1,082]
Purchase of Intangible assets	-	-	-	-	-	-	-	-	-	-	-	-	[400]	[1.788]	[2.188]		-	-	-
Investment in marketable securities	-	-	-	-	-	-	-	-	-	-	[29,276]	[31,409]	[19,426]	(9,253)	(89,364)		(16,352)	(10,653)	(15,000)
Proceeds from maturities of marketable securities	-	-	-	-	-	-	-	-	-	-	-	5,172	9,660	7,445	22,277		16,073	13,434	14,550
Payment related to business combination, net of cash acquired	[15,046]	-	-	-	(15,046)	-	-	-	(20,000)	(20,000)	-	-	-	-	-		-	-	-
Assets acquisition	-	-	-	-	-	-	(3,000)	-	-	[3,000]	-	-	-	-	-		-	-	-
Short term deposits, net	21,997	[46,153]	55,986	(17,052)	14,778	7,849	21,720	18,047	25,721	73,337	18,181	[784]		[32,456]	(15,059)		[2,721]	[12,698]	[9,363]
Net cash (used in) provided by investing activities	4,953	[47,782]	54,824	[18,444]	[6,449]	6,541	17,174	16,568	4,943	45,226	[13,400]	[28,592]	[11,796]	[37,443]	[91,231]		[4,064]	(10,742)	[10,895]
Cash flows from financing activities:																			
Repurchase of common shares	-	(85)	-	-	(85)	-	-	-	-	_	_	-	-	-	-		-	-	-
Proceeds from recapitalization transaction, net	-	-	-	-	-	-	-	29,298	-	29,298	_	-	-	_	-		-	_	-
Payment of dividend	[10,000]	-	-	-	(10,000)	-	-	(100,000)	-	[100,000]	-	-	-	-	-		-	-	-
Exercise if public warranrts	-	-	-	-	-	-	-	-	-	-	-	5	-	-	5		-	-	-
Exercise of options to shares	-	-	-	1,492	1,492	-	187	1,174	944	2,305	3,627	1,056	6,618	1,327	12,628		2,106	5,079	8,130
Proceeds from ESPP, net					-					-			680	657	1,337		624	610	686
Net cash provided by (used in) financing activities	[10,000]	[85]		1,492	(8,593)		187	[69,528]	944	[68,397]	3,627	1,061	7,298	1,984	13,970		2,730	5,689	8,816
Net (decrease) increase in cash and cash equivalents and restricted cash	(10,067)	(25,087)	71,460	15,162	51,468	6,417	31,303	[61,007]	36,168	12,881	(20,310)	(31,604)	[5,054]	284	[56,684]		11,142	11,523	27,099
Net effect of Currency Translation on cash and cash equivalents	[222]	85	306	526	695	[298]	125	(500)	[81]	[754]	56	(2,430)	[2,065]	2,795	[1,644]		185	. 7	(535)
Cash and cash equivalents and restricted cash at beginning of period	81,683	71,394	46,392	118,158	81,683	133,846	139,965	171,393	109,886	133,846	145,973	125,719	91,685	84,566	145,973		87,645	98,972	110,502
Cash and cash equivalents and restricted cash at end of period	\$71,394	\$46,392	\$118,158	\$133,846	\$133,846	\$139,965	\$171,393	\$109,886	\$145,973	\$ 145,973	\$125,719	\$91,685	\$84,566	\$87,645	\$ 87,645	\$	98,972	\$110,502	\$ 137,066
Supplemental cash flow information:			A 15-	A 4.555			A 0.05:	A 86.	A 4 855			A 0 (0-	A 4 105	A 0 505			0.105		
Cash paid for taxes	\$ 149 \$ 107	\$ 484 \$ 88	\$ 699	\$ 1,579	\$ 2,911	\$ 3,407	\$ 2,254 \$ 19	\$ 738 \$ (119)	\$ 1,758	\$ 8,157	\$ 1,287	\$ 2,602	\$ 1,437	\$ 3,727	\$ 9,053	\$	3,625	\$ 4,902	\$ 673
Purchase of property and equipment on suppliers' credit  Purchase of intangible assets	\$ 107 ¢	\$ 88	\$ 58 ¢	\$ [81] \$ -	\$ 172 \$ -	\$ 165 \$ -	\$ 19	\$ (119) \$ -	\$ 749 \$ -	\$ 814 \$ -	\$ 133 \$ -	\$ 88	\$ [79] \$ 171	\$ - \$ 493	\$ 142 \$ 664	\$ \$	-	\$ - \$ -	⊅ - ¢
i di chase vi intangible assets	Φ -	Φ -	ψ -	a -	φ -	Φ -	ψ -	a -	Ψ -	Ψ -	Φ -	φ -	Ф 1/1	Ф 473	ψ 004	Ф	-	·	ψ -

<b>∵</b> Cellebrite			FY 2020					FY 2021					FY 2022	2			FY 2023	
GAAP to Non-GAAP Reconciliations		Ouarte	er Ended		Yr Ended	1	Quarte	r Ended		Yr Ended	1	Ouarte	er Ended		Yr Ended		Quarter Ended	4
[U.S. Dollars in thousands, except share and per share data]	31-Mar	30-Jun	30-Sep	31-Dec	31-Dec	31-Mar	30-Jun	30-Sep	31-Dec	31-Dec	31-Mar	30-Jun	30-Sep	31-Dec	31-Dec	31-Mar	30-Jun	30-Sep
GAAP cost of revenues:																		
Cost of revenues Less:	\$ 9,639	\$ 8,219	\$ 9,501	\$ 10,520	\$ 37,879	\$ 8,199	\$ 10,068	\$ 11,954	\$ 12,336	\$ 42,557	\$ 10,983	\$ 13,098	\$ 14,534	\$ 12,131	\$ 50,746	\$ 12,406	\$ 13,031	\$ 12,878
Dividend participation compensation	-	=	-	-	-	-	-	89	-	89	-	-	-	-	-	-	-	-
Share based compensation expense Acquisition related costs	42	88	79	94	303	78	71	70	71	290	246	339	354	345	1,284	386 13	414 14	435 12
Non-GAAP cost of revenues	\$ 9,597	\$ 8,131	\$ 9,422	\$10,426	\$ 37,576	\$ 8,121	\$ 9,997	\$11,795	\$12,265	\$ 42,178	\$10,737	\$12,759	\$14,180	\$11,786	\$ 49,462	\$ 12,007	\$ 12,603	\$ 12,431
GAAP gross profit:																		
Gross Profit	\$ 29,095	\$ 37,551	\$ 43,740	\$ 46,648	\$ 157,034	\$ 45,084	\$ 49,100	\$ 53,933	\$ 55,572	\$ 203,689	\$ 51,402	\$ 49,475	\$ 57,141	\$ 61,887	\$219,905	\$ 58,828	\$ 63,653	\$ 71,301
Dividend participation compensation Share based compensation expense	<del>-</del> 42	- 88	- 79	94	303	- 78	- 71	89 70	- 71	89 290	246	339	354	345	1,284	386	- 414	435
Acquisition related costs	- 42	-	- '		-		- "	-	-	-	-	-	-	-	- 1,204	13	14	12
Non-GAAP gross profit	\$29,137	\$37,639	\$ 43,819	\$46,742	\$ 157,337	\$45,162	\$49,171	\$54,092	\$ 55,643	\$ 204,068	\$51,648	\$49,814	\$ 57,495	\$ 62,232	\$ 221,189	\$ 59,227	\$ 64,081	\$ 71,748
GAAP operating expenses:																		
Operating expenses	\$ 35,593	\$ 35,886	\$ 34,757	\$ 41,580	\$ 147,816	\$ 40,697	\$ 40,879	\$ 57,025	\$ 51,266	\$ 189,867	\$ 53,348	\$ 55,074	\$ 58,226	\$ 52,213	\$ 218,861	\$ 58,692	\$ 59,030	\$ 57,822
Less:		1,519			1 510													
One time expense  Issuance expenses	-	1,517	-	-	1,519	_	-	11.834	-	11.834	_	-	-	-	_	-	(345)	-
Dividend participation compensation	-	-	-	-	-	-	-	877	-	877	-	-	-	-	-	-	-	-
Share based compensation expense	1,780	1,996	1,746	\$ 1,446	6,968	1,621	1,632	1,347	1,590	6,190	2,612	3,266	3,104	3,442	12,424	4,071	4,186	4,446
Amortization of intangible assets Acquisition related costs	129 1,666	387 1,626	386 1,391	387 1.859	1,289 6,542	388 3.721	436 1,095	541 1.802	607 1,177	1,972 7,795	664 1.058	664 394	664 375	834 133	2,826 1,960	796 251	840 (337)	840 40
Capital loss from FA disposal				689	689	l				-	l				-	-		
Non-GAAP operating expenses	\$32,018	\$30,358	\$31,234	\$37,199	\$ 130,809	\$34,967	\$37,716	\$ 40,624	\$ 47,892	\$161,199	\$49,014	\$50,750	\$ 54,083	\$47,804	\$ 201,651	\$ 53,574	\$ 54,686	\$ 52,496
GAAP operating income (loss)	\$ (6,498)	\$ 1,665	\$ 8,983	\$ 5,068	\$ 9,218	\$ 4,387	\$ 8,221	\$ (3,092)	\$ 4,306	\$ 13,822	\$ (1,946)	\$ [5,599]	\$ (1,085)	\$ 9,674	\$ 1,044	\$ 136	\$ 4,623	\$ 13,479
One-time expense	-	1,519	-	-	1,519	-	-	11.834	-	11,834	-	-	-	-	-	_	(345)	-
Dividend participation compensation	-	-	-	-	-	-	-	966	-	966	-	-	-	-	-	-	-	-
Share based compensation expense	1,822	2,084	1,825	1,540 387	7,271	1,699 388	1,703	1,417	1,661	6,480	2,858	3,605	3,458	3,787 834	13,708	4,457	4,600	4,881
Amortization of intangible assets Acquisition related costs	129 1,666	387 1,626	386 1,391	1,859	1,289 6,542	3,721	436 1,095	541 1,802	607 1,177	1,972 7,795	664 1,058	664 394	664 375	133	2,826 1,960	796 264	840 (323)	840 52
Capital loss from FA disposal			=	689	689	-	-	-	-	-	l	-		-	-		-	-
Non-GAAP operating income (loss)	\$ (2,881)	\$ 7,281	\$12,585	\$ 9,543	\$ 26,528	\$10,195	\$11,455	\$ 13,468	\$ 7,751	\$ 42,869	\$ 2,634	\$ (936)	\$ 3,412	\$14,428	\$ 19,538	\$ 5,653	\$ 9,395	\$ 19,252
GAAP net income (loss)	\$ [7,257]		\$ 8,121	\$ 2,954	\$ 5,781	\$ 3,590	\$ 7,796	\$ 8,139	\$ 51,871	\$ 71,396	\$ 55,438	\$ 33,197	\$ 25,092	\$ 7,078	\$ 120,805	\$ [40,605]	\$ [32,348]	\$ 6,500
One-time expense One-time tax (income) expense	-	1,519	-	-	1,519	-	-	7,067	-	7,067	(1,825)	-	[543]	-	(2,368)	-	-	-
Issuance expenses	-	-	-	-	-	-	-	11,834	-	11,834	- (1,020)	-	-	-	-	-	(345)	-
Dividend participation compensation	1.822	2 084	1.825	1.540	7 071	1,699	1.703	966 1.417	1,661	966 6,480	2.858	3 605	3.458	3.787	13 708	- 4,457	4,600	4.881
Share based compensation expense Amortization of intangible assets	1,822	387	386	387	7,271 1,289	388	435	541	607	1,972	2,838 664	3,605	3,438	3,787	2,826	4,457 796	4,600 840	4,881
Acquisition related costs	1,666	1,626	1,391	1,859	6,542	3,721	1,095	1,802	1,177	7,795	1,058	394	375	133	1,960	264	(323)	52
Capital loss from FA disposal Income tax expense	(78)	- (417)	[207]	689 [441]	689 [1,142]	[804]	[154]	(1,210)	498	(1,670)	(425)	<del>-</del> 506	[981]	516	[384]	1,194	131	(440)
Finance expenses (income)	-				-			[17,252]	[50,621]	[67,873]	[56,348]	[38,391]	[25,091]	2,967	[116,863]	40,793	38,160	9,480
Non-GAAP net income (loss)	\$ (3,718)	\$ 7,162	\$11,516	\$ 6,989	\$ 21,949	\$ 8,594	\$ 10,876	\$ 13,304	\$ 5,193	\$ 37,967	\$ 1,420	\$ [25]	\$ 2,974	\$ 15,315	\$ 19,684	\$ 6,899	\$ 10,715	\$ 21,313
GAAP net income (loss)	\$ (7,257)	\$ 1,963	\$ 8,121	\$ 2,954	\$ 5,781	\$ 3,590	\$ 7,796	\$ 8,139	\$ 51,871	\$ 71,396	\$ 55,438	\$ 33,197	\$ 25,092	\$ 7,078	\$ 120,805	\$ [40,605]	\$ [32,348]	\$ 6,500
Financial (Income) expense Tax expense (income)	(142) 901	(1,015) 717	[417] 1,279	[605] 2,719	[2,179] 5,616	[366] 1,163	[496] 921	(17,812) 6,581	[49,809] 2,244	(68,483) 10,909	(56,400) (984)	[38,466] [330]	(25,422) (755)	572 2,024	[119,716] [45]	38,775 1,966	36,051 920	6,630 349
Depreciation and amortization	1,151	1,506	1,689	1,533	5,879	1,481	1,699	2,097	1,730	7,007	2,112	2,257	2,305	2,520	9,194	2,447	2,569	2,380
One-time expense	-	1,519	-	-	1,519	-	-	11,835	-	11,835	-	-	-	-	-	-	(345)	-
Dividend participation compensation	-	-	-	-	-	-	-	966	-	966	-	-	-	-		-	(345)	-
Share based compensation expense	1,822	2,084	1,825	1,540	7,271	1,699	1,703	1,417	1,661	6,480	2,858	3,605	3,458	3,787	13,708	4,457	4,600	4,881
Acquisition related costs Capital loss from FA disposal	1,666	1,626	1,391	1,859 489	6,542 689	3,721	1,095	1,802	1,177	7,795	1,058	394	375	133	1,960	264	(323)	52 -
Adjusted EBITDA	\$ [1,859]	\$ 8,400	\$13,888	\$10,689	\$ 31,118	\$11,288	\$12,718	\$15,025	\$ 8,874	\$ 47,905	\$ 4,082	\$ 657	\$ 5,053	\$16,114	\$ 25,906	\$ 7,304	\$ 11,124	\$ 20,792
Adjusted EBITDA margin	-4.8%	18.4%	26.1%	18.7%	16.0%	21.2%	21.5%	22.8%	13.1%	19.5%	6.5%	1.0%	7.0%	21.8%	9.6%	10.3%	14.5%	24.7%

: Cellebrite			FY 2020					FY 2021					FY 2022				FY 2023		
			FY 2020					FY ZUZI					FY ZUZZ			F1 2023			
Cellebrite DI Ltd Revenues mix		Quarte	r Ended		Yr Ended		Quarte	r Ended		Yr Ended		Quarte	r Ended		Yr Ended	Quarter Ended			
(U.S. Dollars in thousands - unaudited)	31-Mar	30-Jun	30-Sep	31-Dec	31-Dec	31-Mar	30-Jun	30-Sep	31-Dec	31-Dec	31-Mar	30-Jun	30-Sep	31-Dec	31-Dec	31-Mar	30-Jun	30-Sep	
Revenue by geography:																			
Americas	\$ 21,044	\$ 23,000	\$ 29,944	\$ 26,847	\$ 100,835	\$ 27,135	\$ 30,221	\$ 37,436	\$ 32,137	\$ 126,929	\$ 30,929	\$ 32,443	\$ 41,756	\$ 36,795	\$ 141,923	\$ 37,438	\$ 39,785	\$ 48,273	
EMEA	12,977	13,813	17,532	21,485	65,807	19,671	19,684	21,208	27,910	88,472	23,014	19,623	21,116	29,026	92,779	25,960	26,181	25,952	
APAC	4,713	8,957	5,765	8,836	28,271	6,477	9,263	7,243	7,862	30,845	8,442	10,507	8,803	8,197	35,949	7,836	10,718	9,954	
Total revenue	\$ 38,734	\$ 45,770	\$ 53,241	\$ 57,168	\$ 194,913	\$ 53,283	\$ 59,168	\$ 65,887	\$ 67,908	\$ 246,246	\$ 62,385	\$ 62,573	\$ 71,675	\$ 74,018	\$ 270,651	\$ 71,234	\$ 76,684	\$ 84,179	
Revenue % of total:																			
Americas	54.3%	50.3%	56.2%	47.0%	51.7%	50.9%	51.1%	56.8%	47.3%	51.5%	49.6%	51.8%	58.3%	49.7%	52.4%	52.6%	51.9%	57.3%	
EMEA	33.5%	30.2%	32.9%	37.6%	33.8%	36.9%	33.3%	32.2%	41.1%	35.9%	36.9%	31.4%	29.5%	39.2%	34.3%	36.4%	34.1%	30.8%	
APAC	12.2%	19.6%	10.8%	15.5%	14.5%	12.2%	15.7%	11.0%	11.6%	12.5%	13.5%	16.8%	12.3%	11.1%	13.3%	11.0%	14.0%	11.8%	
Total revenue	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	
Annual recurring revenue (in millions)	99	109	121	137	137	150	159	171	187	187	201	214	232	249	249	261	274	295	
America	55	61	65	73	73	79	82	91	96	96	101	110	122	128	128	136	143	158	
EMEA	32	34	40	47	47	54	57	60	69	69	75	77	82	93	93	95	98	102	
APAC	12	14	16	17	17	17	20	20	22	22	25	27	28	28	28	30	33	35	
Recurring revenue net dollar-based retention rate	128%	138%	140%	142%	142%	148%	142%	139%	137%	137%	128%	128%	129%	130%	130%	128%	125%	125%	